Teva Pharmaceutical Industries Ltd. (TEVA:US) rose to a one-year high after the maker of generic medicines said it plans to return to a deal-making strategy that made it one of the most acquisitive drug companies of the past decade. Teva’s American depositary receipts jumped 6.7 percent to $44.21 at the close in New York yesterday, the highest since May 8, 2012. The drugmaker’s Israel-traded shares gained 7.2 percent to 154.20 shekels at the close today in Tel Aviv.
Help employers find you! Check out all the jobs and post your resume.
